RU2014145121A - Пиримидиновые соединения для лечения злокачественной опухоли - Google Patents
Пиримидиновые соединения для лечения злокачественной опухоли Download PDFInfo
- Publication number
- RU2014145121A RU2014145121A RU2014145121A RU2014145121A RU2014145121A RU 2014145121 A RU2014145121 A RU 2014145121A RU 2014145121 A RU2014145121 A RU 2014145121A RU 2014145121 A RU2014145121 A RU 2014145121A RU 2014145121 A RU2014145121 A RU 2014145121A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- connection
- compound
- cycloalkyl
- malignant tumor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1. Соединение формулы I или формулы II:илигде кольцо А представляет собой 5- или 6-членную гетероарильную группу;пунктирные линии представляют собой необязательные двойные связи;X представляет собой N или О;Y представляет собой атом углерода или гетероатом S или N в кольце А в любом подходящем положении;Rпредставляет собой -RR, где Rпредставляет собой ковалентную связь, C1-C3алкил или линкерную группу, и Rпредставляет собой циклоалкил, гетероциклоалкил, арил, гетероарил, алкилциклоалкил, алкилгетероциклоалкил, алкиларил, алкилгетероарил или алкил, и где Rнеобязательно замещен один, два или три раза независимо выбранными полярными группами;Rпредставляет собой -RR, где Rпредставляет собой ковалентную связь или C1-C3алкил, и Rпредставляет собой циклоалкил, гетероциклоалкил арил, гетероарил или алкил, и где Rнеобязательно замещен от одного до трех раз независимо выбранными полярными группами;Rвыбирают из группы, состоящей из Н, алкила, арила, арилалкила, циклоалкилалкила, гетероциклоалкилалкила, гетероарилалкила и алкоксиалкила, каждый из которых необязательно замещен от одного до трех раз независимо выбранными полярными группами;Rпредставляет собой Н, низший алкил, гало или низший алкокси;или его фармацевтически приемлемая соль.2. Соединение по п. 1, где Rпредставляет собой ковалентную связь.3. Соединение по п. 1, где Rпредставляет собой C1-C3алкилен.4. Соединение по п. 1, где Rпредставляет собой -CH-.5. Соединение по пп. 1-4, где Rпредставляет собой ковалентную связь.6. Соединение по пп. 1-4, где Rпредставляет собой C1-C3алкилен.7. Соединение по пп. 1-4, где Rпредставляет собой -CH-.8. Соединение по пп. 1-4, где Rпредставляет собой фенил, пиперидил, C1-С8алкил или C3-С8циклоалкил, где фенил, пиперидил, алкил или циклоалкил являе
Claims (20)
1. Соединение формулы I или формулы II:
где кольцо А представляет собой 5- или 6-членную гетероарильную группу;
пунктирные линии представляют собой необязательные двойные связи;
X представляет собой N или О;
Y представляет собой атом углерода или гетероатом S или N в кольце А в любом подходящем положении;
R1 представляет собой -R5R6, где R5 представляет собой ковалентную связь, C1-C3алкил или линкерную группу, и R6 представляет собой циклоалкил, гетероциклоалкил, арил, гетероарил, алкилциклоалкил, алкилгетероциклоалкил, алкиларил, алкилгетероарил или алкил, и где R6 необязательно замещен один, два или три раза независимо выбранными полярными группами;
R2 представляет собой -R7R8, где R7 представляет собой ковалентную связь или C1-C3алкил, и R8 представляет собой циклоалкил, гетероциклоалкил арил, гетероарил или алкил, и где R8 необязательно замещен от одного до трех раз независимо выбранными полярными группами;
R3 выбирают из группы, состоящей из Н, алкила, арила, арилалкила, циклоалкилалкила, гетероциклоалкилалкила, гетероарилалкила и алкоксиалкила, каждый из которых необязательно замещен от одного до трех раз независимо выбранными полярными группами;
R4 представляет собой Н, низший алкил, гало или низший алкокси;
или его фармацевтически приемлемая соль.
2. Соединение по п. 1, где R5 представляет собой ковалентную связь.
3. Соединение по п. 1, где R5 представляет собой C1-C3алкилен.
4. Соединение по п. 1, где R5 представляет собой -CH2-.
5. Соединение по пп. 1-4, где R7 представляет собой ковалентную связь.
6. Соединение по пп. 1-4, где R7 представляет собой C1-C3алкилен.
7. Соединение по пп. 1-4, где R7 представляет собой -CH2-.
8. Соединение по пп. 1-4, где R6 представляет собой фенил, пиперидил, C1-С8алкил или C3-С8циклоалкил, где фенил, пиперидил, алкил или циклоалкил является незамещенными или замещенным от 1 до 3 раз сульфоно, гало, амино, нитро, алкилом, алкоксилом, галогеналкилом, циклоалкилом, гетероциклоалкилом, арилом или гетероарилом.
9. Соединение по пп. 1-4, где R8 представляет собой C1-С8алкил или циклогексил, где алкил или циклогексил является незамещенными или замещенным от 1 до 3 раз гидроксилом или амино.
10. Соединение по пп. 1-4, где R3 представляет собой C1-С8алкил, С3-С8циклоалкил, C4-C12циклоалкилалкил, C3-С8гетероциклоалкил, C4-С12гетероциклоалкилалкил, C4-С12арилалкил, C4-С12гетероарилалкил, каждый из которых является незамещенными или замещенным от одного до трех раз гидроксилом, гало или алкокси.
12. Соединение по пп. 1-4, где R4 представляет собой H.
16. Композиция, содержащая соединение по пп. 1-15 в фармацевтически приемлемом носителе.
17. Способ лечения злокачественной опухоли у нуждающегося в этом субъекта, включающий в себя введение упомянутому субъекту соединения по пп. 1-15 в количестве, эффективном для лечения упомянутой злокачественной опухоли.
18. Способ по п. 17, где упомянутую злокачественную опухоль выбирают из группы, состоящей из миелоидного лейкоз, лимфобластного лейкоза, меланомы, злокачественной опухоли молочной железы, легких, толстой кишки, печени, желудка, почки, яичников, матки и головного мозга.
19. Соединение по пп. 1-4 для применения при лечении злокачественной опухоли или при приготовлении лекарственного средства для лечения злокачественной опухоли.
20. Соединение по п. 19, где упомянутую злокачественную опухоль выбирают из группы, состоящей из миелоидного лейкоз, лимфобластного лейкоза, меланомы, злокачественной опухоли молочной железы, легких, толстой кишки, печени, желудка, почки, яичников, матки и головного мозга.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261650000P | 2012-05-22 | 2012-05-22 | |
US61/650,000 | 2012-05-22 | ||
PCT/US2013/042033 WO2013177168A1 (en) | 2012-05-22 | 2013-05-21 | Pyrimidine compounds for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2014145121A true RU2014145121A (ru) | 2016-07-10 |
Family
ID=49624289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014145121A RU2014145121A (ru) | 2012-05-22 | 2013-05-21 | Пиримидиновые соединения для лечения злокачественной опухоли |
Country Status (14)
Country | Link |
---|---|
US (1) | US9567326B2 (ru) |
EP (1) | EP2852579A4 (ru) |
JP (1) | JP2015517574A (ru) |
KR (1) | KR20150018789A (ru) |
CN (1) | CN104302627A (ru) |
AU (1) | AU2013266438B2 (ru) |
BR (1) | BR112014028424A2 (ru) |
CA (1) | CA2873878A1 (ru) |
HK (1) | HK1206338A1 (ru) |
IL (1) | IL235726A0 (ru) |
IN (1) | IN2014DN09610A (ru) |
MX (1) | MX2014013632A (ru) |
RU (1) | RU2014145121A (ru) |
WO (1) | WO2013177168A1 (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011146313A1 (en) | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
EP2763988B1 (en) | 2011-10-03 | 2017-09-20 | The University of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for the treatment of cancer |
MX2014013632A (es) | 2012-05-22 | 2015-02-05 | Univ North Carolina | Compuestos de pirimidina para el tratamiento de cancer. |
WO2014058685A1 (en) * | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
US9562047B2 (en) | 2012-10-17 | 2017-02-07 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
WO2014085225A1 (en) | 2012-11-27 | 2014-06-05 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
CN104926801B (zh) | 2014-03-22 | 2019-06-04 | 浙江大学 | 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用 |
EP3129377A4 (en) * | 2014-04-11 | 2017-12-20 | The University of North Carolina at Chapel Hill | Mertk-specific pyrimidine compounds |
WO2017059280A1 (en) * | 2015-10-02 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Novel pan-tam inhibitors and mer/axl dual inhibitors |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
EP3454856A4 (en) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
EP3475263B1 (en) * | 2016-06-27 | 2022-12-28 | Rigel Pharmaceuticals, Inc. | 2,4-diamino-pyrimidine compounds and their use as irak4 inhibitors |
CN106749173A (zh) * | 2016-11-25 | 2017-05-31 | 吉林化工学院 | 一种嘧啶联吡啶类化合物的制备方法 |
CN110831937A (zh) * | 2017-05-02 | 2020-02-21 | 韩国化学研究院 | 嘧啶衍生物化合物、其光学异构体或其药学上可接受的盐及包含其为有效成分的Tyro3相关疾病的预防或治疗用组合物 |
WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
KR102616469B1 (ko) * | 2020-09-15 | 2023-12-28 | 주식회사 유엔에스바이오 | 혈액 순환 미세체외소체 매개 암 치료용 조성물 |
WO2022059996A1 (ko) * | 2020-09-15 | 2022-03-24 | 서울대학교 기술지주 주식회사 | 혈액 순환 미세체외소체 매개 암 치료용 조성물 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH549339A (de) * | 1971-05-12 | 1974-05-31 | Ciba Geigy Ag | Herbizides mittel. |
US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
WO1997049706A1 (en) | 1996-06-25 | 1997-12-31 | Novartis Ag | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF |
US20080248046A1 (en) | 1997-03-17 | 2008-10-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
MXPA02010693A (es) * | 2000-04-28 | 2003-03-10 | Tanabe Seiyaku Co | Compuestos ciclicos. |
GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
DE60228103D1 (de) | 2001-10-02 | 2008-09-18 | Smithkline Beecham Corp | Chemische verbindungen |
AU2003244098A1 (en) * | 2002-06-28 | 2004-01-19 | Yamanouchi Pharmaceutical Co., Ltd. | Diaminopyrimidinecarboxa mide derivative |
DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
US7589086B2 (en) | 2003-05-28 | 2009-09-15 | Universita Degli Studi Di Siena | Substituted pyrazolo[3,4-D]pyrimidines as anti-tumor agents |
US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
WO2005028434A2 (en) | 2003-09-18 | 2005-03-31 | Conforma Therapeutics Corporation | Novel heterocyclic compounds as hsp90-inhibitors |
EP2260849A1 (en) | 2004-01-21 | 2010-12-15 | Emory University | Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection |
JP2007520559A (ja) | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
PT1713806E (pt) | 2004-02-14 | 2013-08-27 | Irm Llc | Compostos e composições como inibidores da proteína quinase |
EP1749827A4 (en) | 2004-03-30 | 2010-04-21 | Kyowa Hakko Kirin Co Ltd | ANTITUMOR AGENTS |
EP1732541A4 (en) | 2004-04-07 | 2008-03-05 | Takeda Pharmaceutical | CYCLIC COMPOUNDS |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
TW200626574A (en) * | 2004-09-30 | 2006-08-01 | Tibotec Pharm Ltd | HIV inhibiting 5-heterocyclyl pyrimidines |
WO2006042102A2 (en) | 2004-10-05 | 2006-04-20 | Neurogen Corporation | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
EP1710246A1 (en) | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
WO2007032445A1 (ja) * | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
US20070105874A1 (en) | 2005-09-23 | 2007-05-10 | Conforma Therapeutics Corporation | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors |
US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
CN101321751A (zh) * | 2005-09-30 | 2008-12-10 | 布里斯托尔-迈尔斯·斯奎布公司 | Met激酶抑制剂 |
WO2007044426A2 (en) | 2005-10-06 | 2007-04-19 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
WO2007067730A2 (en) | 2005-12-08 | 2007-06-14 | Medarex, Inc. | Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use |
WO2007075554A2 (en) | 2005-12-19 | 2007-07-05 | Osi Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
EP1803723A1 (de) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs |
EP2004632B1 (en) * | 2006-03-30 | 2014-03-12 | Janssen R&D Ireland | Hiv inhibiting 5-amido substituted pyrimidines |
WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
EP2133095A4 (en) | 2007-03-05 | 2012-09-26 | Kyowa Hakko Kirin Co Ltd | PHARMACEUTICAL COMPOSITION |
WO2009032694A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
JP5681855B2 (ja) | 2007-10-12 | 2015-03-11 | アストラゼネカ エービー | プロテインキナーゼの阻害剤 |
CA2703519C (en) | 2007-11-09 | 2017-04-18 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
CA2986640C (en) * | 2008-06-27 | 2019-03-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US8399206B2 (en) | 2008-07-10 | 2013-03-19 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
US20120230991A1 (en) | 2008-07-29 | 2012-09-13 | Douglas Kim Graham | Methods and compounds for enhancing anti-cancer therapy |
WO2010030781A2 (en) | 2008-09-10 | 2010-03-18 | Numed International, Inc. | Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer |
TW201016676A (en) * | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
GB0819105D0 (en) | 2008-10-17 | 2008-11-26 | Chroma Therapeutics Ltd | Pyrrolo-pyrimidine compounds |
WO2010068863A2 (en) | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
US8765727B2 (en) | 2009-01-23 | 2014-07-01 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
TW201102391A (en) | 2009-03-31 | 2011-01-16 | Biogen Idec Inc | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
AR076550A1 (es) * | 2009-05-06 | 2011-06-22 | Portola Pharm Inc | Inhibidores de la janus tirosina kinasa (jak) |
US8840889B2 (en) | 2009-08-13 | 2014-09-23 | The Johns Hopkins University | Methods of modulating immune function |
EP2475668A1 (en) | 2009-09-10 | 2012-07-18 | Novartis AG | Ether derivatives of bicyclic heteroaryls |
WO2011065800A2 (ko) | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
WO2011103441A1 (en) | 2010-02-18 | 2011-08-25 | Schering Corporation | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
WO2011146313A1 (en) | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
JP2014005206A (ja) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
EP2640392B1 (en) | 2010-11-18 | 2015-01-07 | Kasina Laila Innova Pharmaceuticals Private Ltd. | Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof |
US8362023B2 (en) | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
US8889684B2 (en) | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
AU2012302197B2 (en) * | 2011-08-29 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
BR112014006840A2 (pt) | 2011-09-22 | 2017-04-04 | Pfizer | derivados de pirrolopirimidina e purina |
EP2763988B1 (en) | 2011-10-03 | 2017-09-20 | The University of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for the treatment of cancer |
US20160015808A1 (en) | 2012-02-21 | 2016-01-21 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Tam receptors as virus entry cofactors |
LT2840080T (lt) | 2012-04-17 | 2018-02-12 | Fujifilm Corporation | Heterociklinis junginys, turintis azotą, arba jo druska |
IN2012CH01573A (ru) | 2012-04-20 | 2015-07-10 | Advinus Therapeutics Ltd | |
MX2014013632A (es) | 2012-05-22 | 2015-02-05 | Univ North Carolina | Compuestos de pirimidina para el tratamiento de cancer. |
US9562047B2 (en) | 2012-10-17 | 2017-02-07 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
WO2014085225A1 (en) | 2012-11-27 | 2014-06-05 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
US20170202847A1 (en) | 2014-04-04 | 2017-07-20 | The University Of North Carolina At Chapel Hill | Methods for the treatment of tumors |
EP3129377A4 (en) | 2014-04-11 | 2017-12-20 | The University of North Carolina at Chapel Hill | Mertk-specific pyrimidine compounds |
-
2013
- 2013-05-21 MX MX2014013632A patent/MX2014013632A/es unknown
- 2013-05-21 CA CA2873878A patent/CA2873878A1/en not_active Abandoned
- 2013-05-21 CN CN201380025291.3A patent/CN104302627A/zh active Pending
- 2013-05-21 AU AU2013266438A patent/AU2013266438B2/en not_active Expired - Fee Related
- 2013-05-21 RU RU2014145121A patent/RU2014145121A/ru not_active Application Discontinuation
- 2013-05-21 EP EP13793925.2A patent/EP2852579A4/en not_active Withdrawn
- 2013-05-21 KR KR1020147032028A patent/KR20150018789A/ko not_active Application Discontinuation
- 2013-05-21 WO PCT/US2013/042033 patent/WO2013177168A1/en active Application Filing
- 2013-05-21 IN IN9610DEN2014 patent/IN2014DN09610A/en unknown
- 2013-05-21 BR BR112014028424A patent/BR112014028424A2/pt not_active Application Discontinuation
- 2013-05-21 JP JP2015514115A patent/JP2015517574A/ja active Pending
- 2013-05-21 US US14/384,789 patent/US9567326B2/en active Active
-
2014
- 2014-11-16 IL IL235726A patent/IL235726A0/en unknown
-
2015
- 2015-07-20 HK HK15106878.7A patent/HK1206338A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US20150038481A1 (en) | 2015-02-05 |
US9567326B2 (en) | 2017-02-14 |
IN2014DN09610A (ru) | 2015-07-31 |
AU2013266438B2 (en) | 2017-09-07 |
JP2015517574A (ja) | 2015-06-22 |
KR20150018789A (ko) | 2015-02-24 |
HK1206338A1 (en) | 2016-01-08 |
IL235726A0 (en) | 2015-02-01 |
AU2013266438A1 (en) | 2014-12-04 |
WO2013177168A1 (en) | 2013-11-28 |
EP2852579A4 (en) | 2015-12-30 |
MX2014013632A (es) | 2015-02-05 |
CA2873878A1 (en) | 2013-11-28 |
BR112014028424A2 (pt) | 2018-04-24 |
CN104302627A (zh) | 2015-01-21 |
EP2852579A1 (en) | 2015-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2014145121A (ru) | Пиримидиновые соединения для лечения злокачественной опухоли | |
RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
JP2015517574A5 (ru) | ||
RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
RU2016125705A (ru) | Замещенные бензоазепины в качестве модуляторов тoll-подобных рецепторов | |
JP2016503799A5 (ru) | ||
RU2012110246A (ru) | Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора | |
RU2015101106A (ru) | Способ лечения лимфомы, применяя тиенотриазолодиазепиновые соединения | |
RU2013112871A (ru) | Соединения для лечения рака | |
RU2011105768A (ru) | Производные пиперидина в качестве ингибиторов jakз | |
RU2013155586A (ru) | [1,3]оксазины | |
AR079226A1 (es) | Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer | |
RU2012124056A (ru) | Спирооксиндольные антагонисты mdm2 | |
JP2012515776A5 (ru) | ||
JP2017508782A5 (ru) | ||
RU2014125230A (ru) | Пиридонамиды и их аналоги, демонстрирующие противораковую и антипролиферативную активность | |
RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
RU2016134751A (ru) | Соединения | |
AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
RU2013134480A (ru) | Таргетирование раковых опухолей за счет использования ингибиторов изоформ карбоангидразы ix | |
JP2015512943A5 (ru) | ||
JP2013538213A5 (ru) | ||
RU2016147654A (ru) | Соединения для лечения рака | |
RU2009144538A (ru) | Новые циклические пептидные соединения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20171020 |